FDA proposes excluding Novo, Lilly weight loss drugs from bulk compounding list in win for the companies

If that proposal is finalized, the exclusion would likely limit the mass compounding of those medicines ​unless they appear ...
STAT

The FDA’s risky action on compounding weight loss drugs

Gottlieb was commissioner of the Food and Drug Administration from 2017 to 2019. When Makena, a drug designed to prevent preterm births, hit the market in 2011 at $1,500 per dose, it drew rife ...
Forbes

How Compounding Pharmacies Are Challenging Big Pharma On GLP-1 Drugs And Drug Patents

Still life of Ozempic and Wegovy. Both are injectable prescription weight loss medicines. (Photo by: Michael Siluk/UCG/Universal Images Group via Getty Images) As demand surges for semaglutide ...
JD Supra

Compounding and GLP-1s: What To Expect When GLP-1 Drugs Are Removed From FDA’s Drug Shortage List

Since 2022, four GLP-1 drugs, including those indicated for weight loss, have been on FDA’s drug shortage list due to extraordinarily high patient demand. The shortage has, in turn, resulted in ...
JD Supra

Pharmacy compounding under the EU pharma law package

Pharmacy compounding is one of the topics in the EU Pharma Law Package that has perhaps received less attention compared to topics such as regulatory exclusivity rights, shortages, and sustainability.